| Literature DB >> 26371374 |
Denis Leiber1, Fabienne Burlina2, Cillian Byrne2, Philippe Robin1, Christophe Piesse3, Lucie Gonzalez2, Guy Leclercq4, Zahra Tanfin1, Yves Jacquot5.
Abstract
The ERα (oestrogen receptor α)-derived peptide ERα17p activates rapid signalling events in breast carcinoma cells under steroid-deprived conditions. In the present study, we investigated its effects in ELT3 leiomyoma cells under similar conditions. We show that it activates ERK1/2 (extracellular-signal-regulated kinase 1/2), the Gαi protein, the trans-activation of EGFR (epidermal growth factor receptor) and, finally, cell proliferation. It is partially internalized in cells and induces membrane translocation of β-arrestins. The activation of ERK1/2 is abolished by the GPR30 (G-protein-coupled receptor 30) antagonist G15 and GPR30 siRNA. When ERα is down-regulated by prolonged treatment with E2 (oestradiol) or specific ERα siRNA, the peptide response is blunted. Thus the simultaneous presence of GPR30 and ERα is required for the action of ERα17p. In addition, its PLM sequence, which interferes with the formation of the ERα-calmodulin complex, appears to be requisite for the phosphorylation of ERK1/2 and cell proliferation. Hence ERα17p is, to our knowledge, the first known peptide targeting ERα-GPR30 membrane cross-talk and the subsequent receptor-mediated biological effects.Entities:
Keywords: EGFR; ERK1/2; ERα hinge region; GPR30; calmodulin; β-arrestins
Mesh:
Substances:
Year: 2015 PMID: 26371374 DOI: 10.1042/BJ20150744
Source DB: PubMed Journal: Biochem J ISSN: 0264-6021 Impact factor: 3.857